Bayer Schering Pharma AG's Oral Fludara , Approved in Japan
Jan-29-2007
Bayer Schering Pharma AG 's oral Fludara for low-grade non-Hodgkin's lymphoma and mantle cell lymphoma has been approved for marketing in Japan.
Clinical Trials Update: Jan. 25, 2007
Jan-25-2007
Non-Hodgkin's Lymphoma This is an open-label, randomized study for people with relapsed, follicular B-cell lymphoma.
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Jan-25-2007
Biogen Idec today announced that it has initiated a Phase III randomized, double-blind study of an investigational anti-CD80 monoclonal antibody, galiximab, for patients with lymphoma.
Biogen launches human trial of lymphoma drug
Jan-25-2007
Biogen Idec has launched a late-stage human clinical trial of a potential treatment for a form of non-Hodgkin's Lymphoma.
Oral formulation of Fludara approved in Japan
Jan-26-2007
Bayer Schering Pharma AG announced today that the oral formulation of Fludara for low-grade non-Hodgkin's Lymphoma and mantle cell lymphoma has received marketing approval in Japan.